AK104-201
03 Nov 2020
AK104-201
NCT04380805
A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer
Akeso
Cancer Type | Gynaecological |
---|---|
Trial Type | Treatment |
Phase | Phase II |
Age Range | 18+ years |
Sex | Female |
Tumour Stream | Cervical |
Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
Anticipated Start Date | 2020-07-15 |
Anticipated End Date | 2022-02-01 |
Hospital | Ashford Cancer Centre Research |
---|---|
Clinical Trial Coordinator | Sue Yeend |
syeend@adelaidecancercentre.com.au | |
Phone | 08 8292 2240 |
Principal Investigator | Dr Meena Okera |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs